Vis enkel innførsel

dc.contributor.authorKurita, Geana Paula
dc.contributor.authorEkholm, Ola
dc.contributor.authorKaasa, Stein
dc.contributor.authorKlepstad, Pål
dc.contributor.authorSkorpen, Frank
dc.contributor.authorSjøgren, Per
dc.date.accessioned2020-04-27T09:52:10Z
dc.date.available2020-04-27T09:52:10Z
dc.date.created2016-08-23T13:52:42Z
dc.date.issued2016
dc.identifier.citationBrain and Behavior. 2016, 6 (7), .en_US
dc.identifier.issn2162-3279
dc.identifier.urihttps://hdl.handle.net/11250/2652589
dc.description.abstractBackground and purpose The effects of single‐nucleotide polymorphisms (SNPs) on the cognitive function of opioid‐treated patients with cancer until now have not been explored, but they could potentially be related to poor functioning. This study aimed at identifying associations between SNPs of candidate genes, high opioid dose, and cognitive dysfunction. Methods Cross‐sectional multicenter study (European Pharmacogenetic Opioid Study, 2005–2008); 1586 patients; 113 SNPs from 41 genes. Inclusion criteria: cancer, age ≥18 year, opioid treatment, and available genetic data. Cognitive assessment by Mini‐Mental State Examination (MMSE). Analyses: SNPs were rejected if violation of Hardy–Weinberg equilibrium (P < 0.0005), or minor allele frequency <5%; patients were randomly divided into discovery sample (2/3 for screening) and validation sample (1/3 for confirmatory test); false discovery rate of 10% for determining associations (Benjamini–Hochberg method). Co‐dominant, dominant, and recessive models were analyzed by Kruskal–Wallis and Mann–Whitney tests. Results In the co‐dominant model significant associations (P < 0.05) between MMSE scores and SNPs in the HTR3E, TACR1, and IL6 were observed in the discovery sample, but the replication in the validation sample did not confirm it. Associations between MMSE scores among patients receiving ≥400 mg morphine equivalent dose/day and SNPs in TNFRSF1B, TLR5, HTR2A, and ADRA2A were observed, but they could not be confirmed in the validation sample. After correction for multiple testing, no SNPs were significant in the discovery sample. Dominant and recessive models also did not confirm significant associations. Conclusions The findings did not support influence of those SNPs analyzed to explain cognitive dysfunction in opioid‐treated patients with cancer.en_US
dc.language.isoengen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleGenetic variation and cognitive dysfunction in opioid-treated patients with canceren_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber14en_US
dc.source.volume6en_US
dc.source.journalBrain and Behavioren_US
dc.source.issue7en_US
dc.identifier.doi10.1002/brb3.471
dc.identifier.cristin1374875
dc.description.localcodeThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal